Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study

NCT ID: NCT04675528

Last Updated: 2024-07-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-04
• Study Completion Date: 2022-12-12

Brief Summary

To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid tumors.

Conditions

Advanced Solid Tumor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fasting treatment

Group Type: EXPERIMENTAL

DHP107(Oral paclitaxel)

Intervention Type: DRUG

DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)

Fed treatment

Group Type: EXPERIMENTAL

DHP107(Oral paclitaxel)

Intervention Type: DRUG

DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)

Interventions

DHP107(Oral paclitaxel)

DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)

Intervention Type: DRUG

Other Intervention Names

Liporaxel®

Eligibility Criteria

Inclusion Criteria

1. Subjects who are ≥18 years of age on the date of written informed consent.

2. Subjects with histologically or cytologically confirmed advanced solid tumors including but not limited to the listed below for which paclitaxel monotherapy has been determined an appropriate therapy at the investigator's discretion.

• Angiosarcoma
• Bladder cancer
• Breast cancer
• Cervical cancer
• Head and neck cancer (if no difficulty with swallowing)
• Kaposi's sarcoma
• Lung cancer
• Ovarian cancer

3. Subjects who have a life expectancy of ≥12 weeks.

4. Subjects who are able to take oral medication.

5. Subjects who have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.

6. Subjects who have evaluable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).

7. Subjects who have adequate organ functions as indicated by the following laboratory values:

8. Subjects who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and procedures.

9. Subjects who have voluntarily agreed to participate by giving written informed consent.

10. Women of childbearing potential who have negative pregnancy test results at the screening visit and men with female partners of childbearing potential must agree to use adequate contraception for the duration of the trial and up to 90 days after last dose of study drug

Exclusion Criteria

1. Subjects who have history of severe hypersensitive reaction to the active ingredient or any excipients of DHP107.

2. Subjects with following surgical history/medical conditions that may affect drug absorption:

3. Subjects who developed cardiovascular disease (unstable angina, myocardial infarction, stroke, and transient ischemic attack) within 24 weeks prior to study entry, which is deemed to be clinically significant by the investigator.

4. Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection (However, subjects with Gilbert's Syndrome, asymptomatic gallstones, or stable chronic liver disease are, at the discretion of the investigator, eligible for the study. Subjects who are hepatitis B carriers may be eligible if they are on antiviral therapy 2 weeks prior to study entry).

5. Subjects with neuropathy grade > 2 based on CTCAE v5.0 at the time of study entry.

6. Subjects with uncontrolled medical or mental illness that, in the investigator's judgement, could affect treatment tolerability or compliance.

7. Subjects diagnosed with other malignant primary tumor with an exception of the following:

• Malignancy diagnosed at least 5 years previously without evidence of recurrence or persistent disease
• The complete excision of basal/squamous cell carcinoma or papillary thyroid carcinoma or the complete treatment of cervical intraepithelial neoplasia or other in situ carcinoma

8. Subjects with symptomatic or unstable, untreated metastases to the central nervous system (CNS) at the time of screening ('Unstable' means worsening of symptoms within 4 weeks prior to screening).

9. Subjects who are currently receiving alternative cytotoxic agents, regular systemic corticosteroids and medications that could influence drug absorption (e.g. H2-antihistamines, antacids, metoclopramide and charcoal) within 4 weeks prior to entry into the study (C1D1).

10. Subjects who are currently receiving (or unable to stop use the 3 days before the first dose of DHP107 and throughout the study) prescription or non-prescription medications or other products known to be moderate or potent inhibitors/inducers of CYP3A4, P-gp, or CYP2C8.

11. Subjects who cannot intake whole high fat meal offered.

12. Pregnant or breastfeeding women.

13. Subjects who have received any investigational drugs or devices within 4 weeks before the first day of study treatment (C1D1)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erika Hitre, M.D., Ph.D

Role: PRINCIPAL_INVESTIGATOR

National Institute of Oncology

Locations

University of Semmelweis, 1st Internal Medicine Clinic, Department of Clinical Pharmacology

Budapest, , Hungary

National Institute of Oncology

Budapest, , Hungary

University of Debrecen-Clinical Center, Internal Medicine Clinic, Department of Clinical Pharmacology

Debrecen, , Hungary

Clinexpert Ltd Phase I. Studycenter

Gyöngyös, , Hungary

University of Szeged, Dermatology and Allergology Clinic, Phase I. Investigational site

Szeged, , Hungary

Countries

Hungary

Other Identifiers

107CS-7

Identifier Type: -

Identifier Source: org_study_id